Olwen Hahn, MD, specializes in the diagnosis and treatment of breast cancer. Dr. Hahn’s practice primarily focuses on treating patients with all forms of breast cancer. For a comprehensive range of breast cancer treatments, Dr. Hahn offers both standard of care, such as chemotherapy, targeted therapy and endocrine therapy, as well as therapeutic clinical trials in order to deliver the best care for her patients. She is also a proponent of using systemic therapy (chemotherapy, targeted therapy, immunotherapy or endocrine therapy) prior to surgery (neoadjuvant therapy) to better understand how each patient’s individual tumor responds to therapy.
In addition to her clinical practice, Dr. Hahn is committed to elevating cancer care through clinical trials, and is a strong advocate in offering clinical trials to her patients. Additionally, she has worked with the National Cancer Institute (NCI)-sponsored cooperative group Cancer and Leukemia Group B (CALGB) and the Alliance for Clinical Trials in Oncology as an Executive Officer between 2008-2017, where she assisted in the development and conduct of oncology clinical trials. In 2019, she assumed the position of Director and Principal Investigator of the Alliance Central Protocol Operations Program. In this role, Dr. Hahn oversees the clinical operations for a large portfolio of multi-institutional, national oncology studies.
In addition to her clinical practice, Dr. Hahn is committed to elevating cancer care through clinical trials, and is a strong advocate in offering clinical trials to her patients. Additionally, she has worked with the National Cancer Institute (NCI)-sponsored cooperative group Cancer and Leukemia Group B (CALGB) and the Alliance for Clinical Trials in Oncology as an Executive Officer between 2008-2017, where she assisted in the development and conduct of oncology clinical trials. In 2019, she assumed the position of Director and Principal Investigator of the Alliance Central Protocol Operations Program. In this role, Dr. Hahn oversees the clinical operations for a large portfolio of multi-institutional, national oncology studies.
Specialties
Areas of Expertise
Board Certifications
- Internal Medicine
- Medical Oncology
Memberships & Medical Societies
- American Society of Clinical Oncology
Practicing Since
- 2007
Languages Spoken
- English
Medical Education
- Emory University School of Medicine
Residency
- University of Chicago Medicine
Fellowship
- University of Chicago Medicine
News & Research
View Published Papers- T-DM1 and Tucatinib Compared With T-DM1 Alone in Preventing Relapses in People With High Risk HER2-Positive Breast Cancer, the CompassHER2 RD Trial
- CompassHER2-pCR: Decreasing Chemotherapy for Breast Cancer Patients After Pre-surgery Chemo and Targeted Therapy
- A Study Evaluating the Efficacy and Safety of Adjuvant Giredestrant Compared With Physician's Choice of Adjuvant Endocrine Monotherapy in Participants With Estrogen Receptor-Positive, HER2-Negative Early Breast Cancer (lidERA Breast Cancer)
- A Phase III Randomized Trial of Metformin vs Placebo in Early Stage Breast Cancer
- A Study of Tucatinib vs. Placebo in Combination With Capecitabine & Trastuzumab in Patients With Advanced HER2+ Breast Cancer
- Breast Cancer WEight Loss Study (BWEL Study)
- Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
- Cisplatin With or Without Veliparib in Treating Patients With Recurrent or Metastatic Triple-Negative and/or BRCA Mutation-Associated Breast Cancer With or Without Brain Metastases
- Tamoxifen Citrate or Z-Endoxifen Hydrochloride in Treating Patients With Locally Advanced or Metastatic, Estrogen Receptor-Positive, HER2-Negative Breast Cancer
- Fulvestrant and/or Anastrozole in Treating Postmenopausal Patients With Stage II-III Breast Cancer Undergoing Surgery
- Aspirin in Preventing Recurrence of Cancer in Patients With HER2 Negative Stage II-III Breast Cancer After Chemotherapy, Surgery, and/or Radiation Therapy
- PALbociclib CoLlaborative Adjuvant Study
- Aetna HMO (specialists only)
- Aetna POS
- Aetna PPO
- BCBS Blue Precision HMO (specialists only)
- BCBS HMO (HMOI) (specialists only)
- BCBS PPO
- Cigna HMO
- Cigna POS
- Cigna PPO
- CountyCare *see insurance page
- Aetna Better Health *see insurance page
- Medicare
- Multiplan PPO
- PHCS PPO
- United Choice Plus POS/PPO
- United Options (PPO)
- United Select (HMO & EPO) (specialists only)
- United W500 Emergent Wrap
- Aetna Medicare Advantage HMO & PPO
- BCBS Medicare Advantage HMO & PPO
- Humana Medicare Advantage Choice PPO
- Humana Medicare Advantage Gold Choice PFFS
- Humana Medicare Advantage Gold Plus HMO
- United Choice HMO (specialists only)
- University of Chicago Health Plan (UCHP)
Our list of accepted insurance providers is subject to change at any time. You should contact your insurance company to confirm UChicago Medicine participates in their network before scheduling your appointment. If your insurance company is not listed here, or if you have any other questions, please contact Managed.Care@uchospitals.edu.
Duchossois Center for Advanced Medicine (DCAM) - Hyde Park
Request an Appointment at Duchossois Center for Advanced Medicine (DCAM) - Hyde Park
To Refer a Patient
Refer a Patient